These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 34562603)

  • 1. Management of inflammation in cardiovascular diseases.
    Goswami SK; Ranjan P; Dutta RK; Verma SK
    Pharmacol Res; 2021 Nov; 173():105912. PubMed ID: 34562603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.
    Abbate A; Toldo S; Marchetti C; Kron J; Van Tassell BW; Dinarello CA
    Circ Res; 2020 Apr; 126(9):1260-1280. PubMed ID: 32324502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokines as therapeutic targets for cardio- and cerebrovascular diseases.
    Liberale L; Ministrini S; Carbone F; Camici GG; Montecucco F
    Basic Res Cardiol; 2021 Mar; 116(1):23. PubMed ID: 33770265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.
    Esser N; Paquot N; Scheen AJ
    Expert Opin Investig Drugs; 2015 Mar; 24(3):283-307. PubMed ID: 25345753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Chronic Inflammation in Various Diseases and Anti-inflammatory Therapies Containing Natural Products.
    Wang RX; Zhou M; Ma HL; Qiao YB; Li QS
    ChemMedChem; 2021 May; 16(10):1576-1592. PubMed ID: 33528076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Complex Interplay between Lipids, Immune System and Interleukins in Cardio-Metabolic Diseases.
    Bernardi S; Marcuzzi A; Piscianz E; Tommasini A; Fabris B
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30558209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P2X7 Receptors: An Untapped Target for the Management of Cardiovascular Disease.
    Shokoples BG; Paradis P; Schiffrin EL
    Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):186-199. PubMed ID: 32998520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting cytokines and immune checkpoints in atherosclerosis with monoclonal antibodies.
    Lutgens E; Joffre J; van Os B; Ait-Oufella H
    Atherosclerosis; 2021 Oct; 335():98-109. PubMed ID: 34593238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular disease management through restrained inflammatory responses.
    Jabir NR; Tabrez S
    Curr Pharm Des; 2016; 22(7):940-6. PubMed ID: 26648461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expert Group Consensus Opinion: Role of Anti-inflammatory Agents in the Management of Type-2 Diabetes (T2D).
    Das AK; Kalra S; Tiwaskar M; Bajaj S; Seshadri K; Chowdhury S; Sahay R; Indurkar S; Unnikrishnan AG; Phadke U; Pareek A; Purkait I
    J Assoc Physicians India; 2019 Dec; 67(12):65-74. PubMed ID: 31801334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immuno-metabolic interfaces in cardiac disease and failure.
    Bertero E; Dudek J; Cochain C; Delgobo M; Ramos G; Gerull B; Higuchi T; Vaeth M; Zernecke A; Frantz S; Hofmann U; Maack C
    Cardiovasc Res; 2022 Jan; 118(1):37-52. PubMed ID: 33537710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases.
    Aggarwal BB; Harikumar KB
    Int J Biochem Cell Biol; 2009 Jan; 41(1):40-59. PubMed ID: 18662800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapeutic approaches in limiting oxidative stress and inflammation.
    Spychalowicz A; Wilk G; Śliwa T; Ludew D; Guzik TJ
    Curr Pharm Biotechnol; 2012 Oct; 13(13):2456-66. PubMed ID: 22280420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice.
    Tuñón J; Bäck M; Badimón L; Bochaton-Piallat ML; Cariou B; Daemen MJ; Egido J; Evans PC; Francis SE; Ketelhuth DF; Lutgens E; Matter CM; Monaco C; Steffens S; Stroes E; Vindis C; Weber C; Hoefer IE;
    Eur J Prev Cardiol; 2018 Jun; 25(9):948-955. PubMed ID: 29759006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-1 cytokines in cardiovascular disease: diagnostic, prognostic and therapeutic implications.
    Apostolakis S; Vogiatzi K; Krambovitis E; Spandidos DA
    Cardiovasc Hematol Agents Med Chem; 2008 Apr; 6(2):150-8. PubMed ID: 18473780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sortilin and Its Multiple Roles in Cardiovascular and Metabolic Diseases.
    Goettsch C; Kjolby M; Aikawa E
    Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):19-25. PubMed ID: 29191923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging roles of neutrophil-borne S100A8/A9 in cardiovascular inflammation.
    Sreejit G; Abdel Latif A; Murphy AJ; Nagareddy PR
    Pharmacol Res; 2020 Nov; 161():105212. PubMed ID: 32991974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developmental endothelial locus-1 in cardiovascular and metabolic diseases: A promising biomarker and therapeutic target.
    Zhao M; Zheng Z; Li C; Wan J; Wang M
    Front Immunol; 2022; 13():1053175. PubMed ID: 36518760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resolvins as proresolving inflammatory mediators in cardiovascular disease.
    Capó X; Martorell M; Busquets-Cortés C; Tejada S; Tur JA; Pons A; Sureda A
    Eur J Med Chem; 2018 Jun; 153():123-130. PubMed ID: 28732558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammation and cardiovascular disease: from pathogenesis to therapeutic target.
    Golia E; Limongelli G; Natale F; Fimiani F; Maddaloni V; Pariggiano I; Bianchi R; Crisci M; D'Acierno L; Giordano R; Di Palma G; Conte M; Golino P; Russo MG; Calabrò R; Calabrò P
    Curr Atheroscler Rep; 2014 Sep; 16(9):435. PubMed ID: 25037581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.